Article Text

Comparing visual inspection methods for parenteral products in hospital pharmacy: between reliability, cost, and operator formation considerations
    1. 1Service Pharmaceutique, Plateforme FRIPHARM, Groupement Hospitalier Centre, Hôpital Edouard Herriot, Place d’Arsonval, Hospices Civils de Lyon, Lyon, Auvergne-Rhône-Alpes, France
    2. 2Service Biomédical, Groupement Hospitalier Centre, Hôpital Edouard Herriot, Place d’Arsonval, Hospices Civils de Lyon, Lyon, Auvergne-Rhône-Alpes, France
    3. 3Laboratoire de Recherche et Développement de Pharmacie Galénique Industrielle, UMR 5305, Plateforme Fripharm, Faculté de Pharmacie, UCBL, Lyon, Auvergne-Rhône-Alpes, France
    1. Correspondence to Dr Fabrice Pirot, Service Pharmaceutique, Plateforme FRIPHARM, Groupement Hospitalier Centre, Hôpital Edouard Herriot, Place d’Arsonval, Hospices Civils de Lyon, Lyon 69437, France; fabrice.pirot{at}chu-lyon.fr

    Abstract

    Introduction The COVID-19 pandemic has led to unforeseen and novel manifestations, as illustrated by the management of drug shortages through the development of hospital production of sterile pharmaceutical preparations (P2S). Visual inspection of P2S is a release control whose methods are described in monographs of the European Pharmacopoeia (2.9.20) and the United States Pharmacopeia (1790). However, these non-automated visual methods require training and proficiency testing of personnel. The main objective of this work was to compare the reliability and speed of analysis of two visual methods and an automated method for detecting visible particles by image analysis in P2S. Furthermore, these methods were used to evaluate sources of particulate contamination during pre-production processes (washing, disinfection, depyrogenation) and production (filling, capping).

    Materials and methods Three pharmacy technicians examined 41 clear glass vials of type I, 10 and/or 50 mL through manual visual inspection (MVI), semi-automated (SAVI), and automated (AVI) inspection. The vials were distributed as follows: (i) 16 vials of water for injection containing either glass particles (224 µm or 600 µm), stopper fragments, or textile fibres; (ii) five sterile injectable specialties; (iii) 20 vials of water for injection prepared under different pre-production conditions.

    Results and discussion MVI and SAVI detected 100% of visible particles compared with 28% for AVI, which showed a deficiency in detecting textile fibres. All three methods correctly analysed P2S that did not contain visible particles. The three methods detected particles in vials maintained under International Organization for Standardization (ISO) 9 pre-production conditions. However, detections by (i) MVI and SAVI, and by (ii) AVI of particles contained in vials maintained under ISO 8 pre-production conditions were deemed satisfactory and unsatisfactory, respectively.

    Conclusion The importance of visual inspection of P2S requires rapid, sensitive, and reliable detection methods. In this context, MVI and SAVI have proven to be more effective than AVI for a more competitive financial, training, and implementation investment.

    • Drug Compounding
    • Environment, Controlled
    • Equipment Design
    • PHARMACEUTICAL PREPARATIONS
    • Pharmacopoeia
    • PHARMACY SERVICE, HOSPITAL
    • Quality Assurance, Health Care
    • Safety

    Data availability statement

    No data are available.

    http://creativecommons.org/licenses/by-nc/4.0/

    This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

    Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Supplementary materials

    • Supplementary Data

      This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.